Axon Targeting’s Switch Lives in the Cell Body Observed Here, Not Operated Athithi Verma September 17, 2026 Regeneration programmes can make axons grow. If targeting is transcriptional, growth was always the achievable half of a two-part problem. NICE Withdrew Four Appraisals Because the Medicine Went Off Patent.ย CMS Added Five Tracks to ACCESS. The Payer Pledge Covers 165 Million People Who Cannot Join It. Radiopharmaceuticals: sixteen years of deal data on where the field goes next The UK Commission Wants L-Plates for AI and an End to One-Time Approval Lilly Confirmed the Calculations Were Wrong. A Jury Is Deciding What That Cost Nektar. Editor’s Pick In Ustekinumab Biosimilars, Approval Stopped Being the Hard Part In Japan, Expanding a Label Is What Triggers the Price Cut AstraZeneca Announced Nothing. The Market Charged It $24bn Anyway.NeuroPulse NeuroPulse Wk 33: Jazz Bet $820M on a New FDA Evidence Standard NeuroPulse Wk 32: Takeda Fixed the Cause, and Cannot Ship It YetOrphanPulse OrphanPulse Wk 33: The Competitor Got a PDUFA Date Five Days Later OrphanPulse Wk 32: Tarsus Paid $450M Upfront for a Readout in 2029DealPulse Signal DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of ItDealPulse Report DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the Lead DealFlow H1 2026: M&A Doubles as Upfront Spending Hits $174BThe Beats DealPulse Signal Wk 33: Rare Disease Took Two Thirds of the Week DealPulse Signal Wk 32: Private Equity Took the Week and Paid Cash for All of It DealPulse Report July 2026: Vertex Pays 102% as Oncology Cedes the LeadAnalysis Radiopharmaceuticals: sixteen years of deal data on where the field goes next Behind the Headlines: How the Leaders Really Performed 7 Market Access Trends Reshaping Pharmaย by 2027Coverage The ADC Decade Accelerates: What to Watch at ASCO 2026The Briefs Axon Targeting’s Switch Lives in the Cell Body Observed Here, Not Operated Athithi Verma September 17, 2026 NICE Withdrew Four Appraisals Because the Medicine Went Off Patent.ย Athithi Verma September 17, 2026 CMS Added Five Tracks to ACCESS. The Payer Pledge Covers 165 Million People Who Cannot Join It. Athithi Verma September 17, 2026 The UK Commission Wants L-Plates for AI and an End to One-Time Approval Athithi Verma September 16, 2026 Lilly Confirmed the Calculations Were Wrong. A Jury Is Deciding What That Cost Nektar. Athithi Verma September 16, 2026 Years After NCCN Recommended It, FET-PET Finally Has an FDA-Approved Drug Athithi Verma September 15, 2026 Read More
Axon Targeting’s Switch Lives in the Cell Body Observed Here, Not Operated Athithi Verma September 17, 2026 Regeneration programmes can make axons grow. If targeting is transcriptional, growth was always the achievable half of a two-part problem.
Axon Targeting’s Switch Lives in the Cell Body Observed Here, Not Operated Athithi Verma September 17, 2026
NICE Withdrew Four Appraisals Because the Medicine Went Off Patent.ย Athithi Verma September 17, 2026
CMS Added Five Tracks to ACCESS. The Payer Pledge Covers 165 Million People Who Cannot Join It. Athithi Verma September 17, 2026
The UK Commission Wants L-Plates for AI and an End to One-Time Approval Athithi Verma September 16, 2026
Lilly Confirmed the Calculations Were Wrong. A Jury Is Deciding What That Cost Nektar. Athithi Verma September 16, 2026
Years After NCCN Recommended It, FET-PET Finally Has an FDA-Approved Drug Athithi Verma September 15, 2026